{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:14:00Z","timestamp":1793301240797,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clon.2026.104075","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:39:10Z","timestamp":1770449950000},"page":"104075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Differential Efficacy of Immunotherapy for Hepatocellular Carcinoma by Aetiology: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"52","author":[{"given":"Y.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2598-2525","authenticated-orcid":false,"given":"C.","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clon.2026.104075_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clon.2026.104075_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3350\/cmh.2022.0316","article-title":"Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study","volume":"29","author":"Choi","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.clon.2026.104075_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","author":"Seyhan","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"7854","key":"10.1016\/j.clon.2026.104075_bib4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.clon.2026.104075_bib5","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.cell.2019.10.038","article-title":"Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma","volume":"179","author":"Gao","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.clon.2026.104075_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"issue":"20","key":"10.1016\/j.clon.2026.104075_bib7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clon.2026.104075_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"5","key":"10.1016\/j.clon.2026.104075_bib9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"issue":"10492","key":"10.1016\/j.clon.2026.104075_bib10","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clon.2026.104075_bib11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"issue":"10","key":"10.1016\/j.clon.2026.104075_bib12","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/oncolo\/oyae110","article-title":"Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy","volume":"29","author":"Cowzer","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.clon.2026.104075_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/JHC.S436804","article-title":"Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States","volume":"11","author":"Bteich","year":"2024","journal-title":"J Hepatocellular Carcinoma"},{"issue":"1","key":"10.1016\/j.clon.2026.104075_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s44276-024-00038-w","article-title":"Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors","volume":"2","author":"Wu","year":"2024","journal-title":"BJC Rep"},{"issue":"3","key":"10.1016\/j.clon.2026.104075_bib15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2019.05.014","article-title":"Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis","volume":"71","author":"Yau","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.clon.2026.104075_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111947","article-title":"Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors","volume":"132","author":"Zou","year":"2024","journal-title":"Int Immunopharmacology"},{"issue":"5","key":"10.1016\/j.clon.2026.104075_bib17","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1002\/cam4.5337","article-title":"Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study","volume":"12","author":"Hatanaka","year":"2023","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.clon.2026.104075_bib18","doi-asserted-by":"crossref","first-page":"e922","DOI":"10.1093\/oncolo\/oyae048","article-title":"Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma","volume":"29","author":"Su","year":"2024","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.clon.2026.104075_bib19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10637-022-01248-0","article-title":"Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience","volume":"40","author":"Wu","year":"2022","journal-title":"Investig New Drugs"},{"issue":"3","key":"10.1016\/j.clon.2026.104075_bib20","doi-asserted-by":"crossref","first-page":"193-+","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2026.104075_bib21","doi-asserted-by":"crossref","first-page":"E249","DOI":"10.1111\/ajco.13454","article-title":"Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center","volume":"17","author":"Ng","year":"2021","journal-title":"Asia-Pacific J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clon.2026.104075_bib22","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1002\/cam4.5506","article-title":"Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma","volume":"12","author":"Su","year":"2023","journal-title":"Cancer Med"},{"issue":"10415","key":"10.1016\/j.clon.2026.104075_bib23","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.clon.2026.104075_bib24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104075_bib25","article-title":"Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China","volume":"13","author":"Liu","year":"2022","journal-title":"Front Genet"},{"issue":"7","key":"10.1016\/j.clon.2026.104075_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071722","article-title":"Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers","volume":"14","author":"Himmelsbach","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.clon.2026.104075_bib27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/oncolo\/oyae142","article-title":"Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study","volume":"29","author":"Storandt","year":"2024","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.clon.2026.104075_bib28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1159\/000537915","article-title":"Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study","volume":"13","author":"Rossari","year":"2024","journal-title":"Liver Cancer"},{"issue":"10474","key":"10.1016\/j.clon.2026.104075_bib29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clon.2026.104075_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clon.2026.104075_bib31","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00432-023-04590-9","article-title":"Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis","volume":"149","author":"Brown","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10474","key":"10.1016\/j.clon.2026.104075_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2026.104075_bib33","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2147\/JHC.S461630","article-title":"Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study","volume":"11","author":"Zheng","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"issue":"19","key":"10.1016\/j.clon.2026.104075_bib34","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2026.104075_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"issue":"7","key":"10.1016\/j.clon.2026.104075_bib36","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clon.2026.104075_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial","volume":"9","author":"Ferris","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.clon.2026.104075_bib38","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clon.2026.104075_bib39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.canlet.2018.11.001","article-title":"Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma","volume":"442","author":"Koemans","year":"2019","journal-title":"Cancer Lett"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:02:05Z","timestamp":1775502125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526000464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"alternative-id":["S0936655526000464"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104075","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential Efficacy of Immunotherapy for Hepatocellular Carcinoma by Aetiology: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104075"}}